Human FHL2 knockout U-2 OS cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
FHL2 KO cell lysate available now. KO validated by Immunocytochemistry, Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift = 96.21%.
View Alternative Names
AAG 11, Aging associated gene 11, DRAL, Down regulated in rhabdomyosarcoma LIM protein, FHL2 protein, FHL2_HUMAN, Four and a half LIM domain protein 2, Four and a half LIM domains 2, Four and a half LIM domains protein 2, KIAA0990, LIM domain protein DRAL, SLIM-3, Skeletal muscle LIM-protein 3
- WB
Lab
Western blot - Human FHL2 knockout U-2 OS cell lysate (AB263928)
Lane 1 : Wild-type U-2 OS cell lysate
Lane 2 : FHL2 knockout U-2 OS cell lysate
Lane 3 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lanes 1 - 3 : Merged signal (red and green). Green - ab202586 observed at 32 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
ab202586 was shown to react with FHL2 in wild-type U-2 OS cells in western blot with loss of signal observed in FHL2 knockout sample. Wild-type and FHL2 knockout U-2 OS cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab202586 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-FHL2 antibody [EPR17860-23] (<a href='/en-us/products/primary-antibodies/fhl2-antibody-epr17860-23-ab202586'>ab202586</a>) at 1/1000 dilution
Lane 1:
Wild-type U-2 OS cell lysate at 40 µg
Lane 2:
FHL2 knockout U-2 OS cell lysate at 40 µg
Lane 3:
HeLa cell lysate at 40 µg
Predicted band size: 32 kDa
false
- WB
Lab
Western blot - Human FHL2 knockout U-2 OS cell lysate (AB263928)
Lane 1 : Wild-type U-2 OS cell lysate
Lane 2 : FHL2 knockout U-2 OS cell lysate
Lane 3 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lanes 1 - 3 : Merged signal (red and green). Green - ab202584 observed at 32 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
ab202584 was shown to react with FHL2 in wild-type U-2 OS cells in western blot with loss of signal observed in FHL2 knockout cell line ab262496 (knockout cell lysate ab263928).Wild-type and FHL2 knockout U-2 OS cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab202584 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-FHL2 antibody [EPR17860-20] (<a href='/en-us/products/primary-antibodies/fhl2-antibody-epr17860-20-ab202584'>ab202584</a>) at 1/1000 dilution
Lane 1:
Wild-type U-2 OS cell lysate at 40 µg
Lane 2:
FHL2 knockout U-2 OS cell lysate at 40 µg
Lane 2:
Western blot - Human FHL2 knockout U-2 OS cell line (<a href='/en-us/products/cell-lines/human-fhl2-knockout-u-2-os-cell-line-ab262496'>ab262496</a>)
Lane 3:
HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 40 µg
Predicted band size: 32 kDa
Observed band size: 32 kDa
false
- NGS
Supplier Data
Next Generation Sequencing - Human FHL2 knockout U-2 OS cell lysate (AB263928)
Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift = 96.21%
Reactivity data
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The FHL2 protein serves critical functions in muscle development and differentiation. It operates as part of a multiprotein complex that interacts with cytoskeletal components contributing importantly to muscle cell adhesion and communication. Moreover FHL2 engages in transcriptional regulation and acts as a coactivator or corepressor of specific transcription factors influencing gene expression patterns relevant to muscle function and maintenance.
Pathways
The FHL2 protein plays significant roles in Wnt and MAPK signaling pathways. In the Wnt signaling pathway FHL2 regulates the transcriptional activity of beta-catenin an essential component of the pathway involved in cell growth and differentiation. Additionally FHL2 contributes to the MAPK signaling pathway by influencing interactions between upstream regulators and downstream targets modulating cellular responses to external stimuli. Through these pathways FHL2 interacts with various proteins including GATA4 and TEF-1 which are vital for its regulatory functions.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Female
Complementary Products
![Western blot - Anti-FHL2 antibody [EPR17860-20] (AB202584)](https://content.abcam.com/products/images/fhl2-antibody-epr17860-20-ab202584--western-blot-img43043.jpg)
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com